The stock of Concordia International Corp (NASDAQ:CXRX) hit a new 52-week low and has $2.85 target or 12.00% below today’s $3.24 share price. The 5 months bearish chart indicates high risk for the $173.96M company. The 1-year low was reported on Nov, 1 by Barchart.com. If the $2.85 price target is reached, the company will be worth $20.88 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 691,303 shares traded hands. Concordia International Corp (NASDAQ:CXRX) has declined 85.98% since March 30, 2016 and is downtrending. It has underperformed by 89.00% the S&P500.
Analysts await Concordia International Corp (NASDAQ:CXRX) to report earnings on November, 10. They expect $1.35 earnings per share, up 3.05% or $0.04 from last year’s $1.31 per share. CXRX’s profit will be $72.48M for 0.60 P/E if the $1.35 EPS becomes a reality. After $1.21 actual earnings per share reported by Concordia International Corp for the previous quarter, Wall Street now forecasts 11.57% EPS growth.
Concordia International Corp (NASDAQ:CXRX) Ratings Coverage
Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The rating was maintained by Scotia Capital with “Sector Outperform” on Tuesday, September 29. IBC downgraded Concordia International Corp (NASDAQ:CXRX) on Monday, August 15 to “Underperformer” rating. The firm has “Neutral” rating given on Monday, June 6 by Goldman Sachs. The company was maintained on Tuesday, August 11 by Canaccord Genuity. The firm earned “Sector Perform” rating on Monday, November 30 by IBC. The rating was maintained by Scotia Capital on Friday, October 16 with “Sector Outperform”. The stock of Concordia International Corp (NASDAQ:CXRX) has “Neutral” rating given on Monday, August 15 by Goldman Sachs. Mackie upgraded the stock to “Speculative Buy” rating in Monday, October 19 report. The firm earned “Hold” rating on Thursday, August 4 by TD Securities. GMP Securities downgraded the shares of CXRX in a report on Monday, August 15 to “Hold” rating.
According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”
More notable recent Concordia International Corp (NASDAQ:CXRX) news were published by: Prnewswire.com which released: “Concordia International Corp. Announces CEO Transition Plan” on October 21, 2016, also Prnewswire.com with their article: “Concordia International Corp. Announces Release Date for Third Quarter 2016 …” published on October 26, 2016, Prnewswire.com published: “Shareholder Class Action Filed Against Concordia International Corp. – CXRX” on August 17, 2016. More interesting news about Concordia International Corp (NASDAQ:CXRX) were released by: Business.Financialpost.com and their article: “Concordia International Corp takeover unlikely â€“ Goldman” published on September 27, 2016 as well as Prnewswire.com‘s news article titled: “Concordia International Corp. Announces FDA Approval for New Photofrin® Laser” with publication date: June 30, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.